Jean‐Damien Charrier

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

Philip M. Reaper, Matthew R. Griffiths, Joanna Long et al. · Nature Chemical Biology · 2011 · 631 citations

Tumor Biology, P53-deficient Cancer Cells, Selective Killing +9

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

Jean‐Damien Charrier, Steven J. Durrant, Julian M.C. Golec et al. · Journal of Medicinal Chemistry · 2011 · 256 citations · Full text

Chemoprevention Strategy, Molecular Biology, Molecular Pharmacology +19

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

Amy B. Hall, Dave Newsome, Yuxin Wang et al. · Oncotarget · 2014 · 189 citations · Full text

The discovery of the potent aurora inhibitor MK-0457 (VX-680)

David Bebbington, Hayley Binch, Jean‐Damien Charrier et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 99 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Medicine +8

Discovery and Structure−Activity Relationship of 3-Aminopyrid-2-ones as Potent and Selective Interleukin-2 Inducible T-Cell Kinase (Itk) Inhibitors

Jean‐Damien Charrier, Andrew T. Miller, David P. Kay et al. · Journal of Medicinal Chemistry · 2011 · 60 citations · Full text

Kinase Active Site, Medicinal Chemistry, Drug Target +14